🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  2. PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  3. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  4. PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  6. Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion

    Gilead Sciences International Limited

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  7. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  8. Placebo Injection, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  9. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Roche Registration Limited

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  10. Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  11. Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Pharma Mar S.A.

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  12. Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.

    GlaxoSmithKline Biologicals S.A.

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  13. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  14. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  15. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    Argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  16. Placebo is identical to the active drugs but without the active drug substance to maintain study blinding. Niraparib placebo tablets, Dostarlimab placebo infusion bags, JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  17. Placebo matching DNTH103, DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  18. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Pharma Mar S.A.

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  19. Placebo of Eliquis 2.5 mg, Eliquis 2.5 mg film-coated tablets

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  20. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  21. Placebo to Match Tinlarebant (LBS-008). Placebo tablets will be prepared similarly with microcrystalline cellulose used in place of the active drug substance. The placebo tablet is identical in size, appearance, and other physical properties to the LBS-008 tablet., LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Geographic Atrophy

    phase 3 small molecule active

    1 trial

  22. Placebo to match 100mg tablet, Lasmiditan, LASMIDITAN, Placebo to match 50mg tablet, LASMIDITAN, Placebo to match 100mg film coated tablet, Lasmiditan, Placebo to match 25mg tablet, Lasmitidan, Placebo to match 50mg film coated tablet

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  23. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  24. Placebo to match LY, Brenipatide, Brenipatide, Brenipatide

    Eli Lilly Co.

    Alcohol Use Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources